At Arsia, we envision a world in which medicines are delivered to patients easily, painlessly, and effectively. We're turning this vision into reality. Find out how.

News About Arsia

NOV 11, 2016

Eagle Pharmaceuticals Enters Into Definitive Agreement to Acquire Arsia Therapeutics

Eagle to create Biologics Innovation Center located in Kendall Square in Cambridge, MA
DEC 24, 2015 - STAT

Amy Schulman named one of '3 people to watch in Kendall Square in 2016'

Schulman moved to the Boston area last year to become the first female venture partner at Polaris. The former general counsel of Pfizer, she is also chief executive of two early-stage companies based in Kendall’s LabCentral, Arsia and Lyndra, both of which seem poised for growth in 2016.
DEC 18, 2015

Arsia Therapeutics Presents Scientific Progress in Creating High-Concentration Biotherapeutics

Charles Wescott, VP of Research and Development, Presents at The 13th Annual US-Japan Symposium on Drug Delivery Systems
DEC 16, 2015 - Boston Globe

Cambridge startup teams up with Biogen on hemophilia drugs

Two-year-old Cambridge startup Arsia Therapeutics Inc. said Wednesday that it has struck a research collaboration with biotech giant Biogen Inc. to develop a system for delivering drugs to hemophilia patients through under-the-skin injections.
DEC 16, 2015

Arsia and Biogen Sign Research Collaboration for Development of Subcutaneous Biologics

Companies will collaborate to create subcutaneous products for treatment of hemophilia in agreement valued up to $100M
DEC 14, 2015 - BioCentury

Subcutaneous Solution

Subcutaneous delivery of biologics can eliminate or reduce visits to a hospital or doctor's office, but at the high concentrations required, an increase in interactions between the molecules causes most biologics to become too viscous and painful to administer subcutaneously. Arsia Therapeutics Inc. is developing a library of excipients that disrupt the interactions between the protein molecules without interfering with the proteins themselves.
JUN 18, 2014 - Big3Bio

Arsia In the Spotlight

For the “In the Spotlight” section of its 10x publication, Janssen Labs chatted with Ellie McGuire and Paulina Hill to learn more about the company’s technology, the need for this approach and what the name Arsia really means.
An Arsia scientist takes measurements to help develop high-concentration low-viscosity biologic pharmaceuticals.An Arsia scientist works in our Kendall Square, Cambridge lab producing formulating high-concentration biopharmaceuticals.Every protein is different. Arsia’s technology is based on a library of proprietary viscosity-reducing excipients. Low-viscosity, stable formulations for a target protein are developed by a cycle of library screening, viscosity optimization, and stability testing.Arsia CEO Amy Schulman works directly with the team in the lab in Cambridge, MA.  Amy is a Venture Partner at Polaris Partners.An Arsia scientist works in our Kendall Square, Cambridge lab producing formulating high-concentration biopharmaceuticals.